A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/35 (2006.01) A61K 31/365 (2006.01) A61K 31/37 (2006.01) A61M 1/36 (2006.01) A61N 5/06 (2006.01)
Patent
CA 2117330
The occurence of restenosis following percutaneous transluminal coronary angioplasty is prevented or inhibited using a photopheresis treatment method. In accordance with the photopheresis treatment method, a photoactive compound such as 8-methoxypsoralen is administered to the patient's blood or affected tissue, or some fraction thereof, in vitro or in vivo using conventional administration routes. A portion of the patient's blood or affected tissue is then treated (preferably, extracorporeally) using photopheresis, which comprises subjecting the blood or affected tissue to electromagnetic radiation in a wavelength suitable for activating the photoactive compound, such as ultraviolet light, preferably long wavelength ultraviolet light in the wavelength range of 320 to 400 nm, commonly called UVA light. The treated blood or affected tissue, or a fraction thereof, is returned to the patient (in the case of extracorporeal photopheresis) or remains in the patient (following in vivo photopheresis).
Bisaccia Emil
Klainer Albert S.
Bisaccia Emil
Klainer Albert S.
Shapiro Cohen
LandOfFree
The use of psoralen compounds to inhibit restenosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with The use of psoralen compounds to inhibit restenosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and The use of psoralen compounds to inhibit restenosis... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1565850